Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.9152W HIGH $28.75
Volume
20.27 K
Value Traded
133.79 K
Short % Float
16.12%
Days to Cover
7.2
+4.93%Week
-14.19%1 Month
-31.04%3 Month
-44.37%6 Month
-99.9%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.96 M
EPS (TTM)
-2.64
P/E Ratio
-
Ent. Value
6.00 M
Total Shares
2.06 M
Float Shares
1.73 M
Insiders
16.00%
Institutions
5.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GTBP Catalyst Timeline
Dated clinical, regulatory and corporate events for GT Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for GT Biopharma, Inc.
105Total events
13Upcoming
9Tier-1 (high impact)
2004 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceGTB-5550IND
FDA clears new IND for GTB-5550 in multiple myeloma under IST protocol
multiple myelomasource ↗
●Enrollment UpdateGTB-5550Trial
Phase 1 dose escalation basket trial of GTB-5550 in solid tumors continues to actively enroll
solid tumorssource ↗
●R&D DayPresentation
GT Biopharma to host live company presentation on TriKE platform development for cancer treatment
blood cancers and solid tumorssource ↗
▲Enrollment CompleteGTB-3650Trial
Cohort 4 enrollment completed in GTB-3650 trial
CD33 positive hematologic malignanciessource ↗
●Enrollment UpdateGTB-3650Trial
Enrollment of Cohort 5 in progress for GTB-3650
CD33 positive hematologic malignanciessource ↗
▲Enrollment CompleteGTB-5550Trial
Cohort 1 enrollment completed in GTB-5550 trial
B7-H3 positive solid tumorssource ↗
●Enrollment UpdateGTB-5550Trial
Enrollment in Cohort 2 in progress for GTB-5550
B7-H3 positive solid tumorssource ↗
▲Enrollment MilestoneGTB-3650Trial
Cohort 4 complete in GTB-3650 Phase 1 trial
CD33 positive hematologic malignanciessource ↗
▲Enrollment MilestoneGTB-5550Trial
Cohort 1 complete in GTB-5550 Phase 1 trial
B7-H3 positive solid tumorssource ↗
▲First Patient DosedGTB-5550Trial
First patient dosed in Phase 1 trial of GTB-5550
B7-H3 positive solid tumorssource ↗
▲Trial InitiationGTB-5550Trial
Phase 1 basket trial initiated for GTB-5550
B7-H3 positive solid tumorssource ↗
◆Enrollment UpdateGTB-5550Trial
Enrollment commencement expected mid-2026
solid tumors expressing B7-H3source ↗
◆Trial InitiationGTB-5550Trial
Phase 1 dose escalation basket trial initiation expected mid-2026
solid tumors expressing B7-H3source ↗
◆Enrollment MilestoneGTB-3650Trial
Initiate dosing in Cohort 5 expected Q2 2026
CD33 positive leukemiassource ↗
◆Oral PresentationPresentation
GT Biopharma to present at Centurion One Capital 9th Annual Toronto Growth Conference
◆Enrollment UpdateGTB-3650Trial
Enrollment ongoing in Cohort 4; next update anticipated Q3 2026
CD33 positive leukemiassource ↗
●Enrollment UpdateGTB-3650Trial
Phase 1 GTB-3650 trial advancing to Cohort 4 at 10 μg/kg/day
relapsed or refractory blood cancers expressing CD33 (AML, high-risk MDS)source ↗
◆Timing GuidanceGTB-3650Presentation
Next update expected in Q1 2026
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
◆Topline ReadoutGTB-3650Clinical Data
Next trial update for GTB-3650 expected in Q1 2026
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲Enrollment CompleteGTB-3650Trial
Cohort 4 enrollment completed in GTB-3650 trial
CD33 positive hematologic malignanciessource ↗
▲Enrollment CompleteGTB-5550Trial
Cohort 1 enrollment completed in GTB-5550 trial
B7-H3 positive solid tumorssource ↗
●IND SubmissionGTB-5550IND
IND submission for GTB-5550 TriKE
B7-H3 expressing solid tumor cancerssource ↗
●Enrollment UpdateGTB-3650Trial
Phase 1 trial of GTB-3650 actively enrolling, advanced to Cohort 4 at 10 µg/kg/day
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲First Patient DosedGTB-3650Trial
Anticipated initiation of dosing in Cohort 4
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
◆R&D DayPresentation
GT Biopharma to participate in Centurion One Capital 3rd Annual Bahamas Summit
▲Enrollment UpdateGTB-3650Trial
Cohort 3 formal safety review completed, advancement into Cohort 4
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
●IND SubmissionGTB-5550IND
GTB-5550 TriKE IND submission for B7H3 positive solid tumors expected in Q4 2025
B7H3 positive solid tumorssource ↗
●Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation
▲First Patient DosedGTBP-3650Trial
Phase 1 trial of GTBP-3650 continues to enroll as expected
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲Enrollment UpdateGTB-3650Trial
Enrollment momentum in Phase 1 trial of GTB-3650; moving into third dose cohort
relapsed or refractory CD33 expressing hematologic malignancies (AML, MDS)source ↗
▲First Patient DosedGTB-3650Trial
First patient in Cohort 3 completed first week of cycle 1
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲Enrollment CompleteGTB-3650Trial
Cohort 2 enrollment completed with safety review passed
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲First Patient DosedGTB-3650Trial
First patient dosed in Cohort 2
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲Enrollment CompleteGTB-3650Trial
Cohort 1 enrollment completed
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲First Patient DosedGTB-3650Trial
First patient dosed in Phase 1 trial of GTB-3650
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
▲First Patient DosedGTB-3650Trial
First patient dosed in Phase 1 trial of GTB-3650
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
◆Topline ReadoutGTBP-3650Clinical Data
Initial results from multiple dose cohorts of GTBP-3650 expected later in 2025
relapsed or refractory CD33 expressing hematologic malignanciessource ↗
◆Topline ReadoutGTB-3650Clinical Data
Initial clinical data for GTB-3650
CD33+ hematologic malignanciessource ↗
◆Trial InitiationGTB-5550Trial
Phase 1 dose escalation basket trial initiation for GTB-5550
B7H3 positive solid tumors (prostate, breast, head and neck, ovarian, lung, GI)source ↗
Past FDA Catalysts and PDUFA Decisions
How GTBP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | GTB-3650 (TriKE® natural killer cell engager) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every GTBP program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Breen Michael MartinDirector, Officer (Executive Chairman/Interim CEO) | Buy | 50,000 656,218 held | $0.50 | 04/11/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in GTBP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GTBP for Q2 2026. | ||||
GTBP Institutional Ownership Trends
GTBP Short Interest
Shares sold short, counted twice a month.
16.12%
Short % of Float
of tradable shares sold short
278.8K
Shares Sold Short
+7.5% vs prior count
7.2 High
Days to Cover
trading days of normal volume to buy every short share back
38.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GTBP ranks across every disease it competes in
Competitive Position is a premium feature
See how GTBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGTBP News
GTBP▼ -7.1%on this news
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
GT Biopharma has been selected for an oral presentation at the SITC 2026 Annual Meeting. The presentation will discuss how inhibiting the KRAS oncoprotein can enhance the effectiveness of NK cell immunotherapy for pancreatic cancer. This event will take place in Phoenix, AZ, from November 4-8, 2026.
Read more →GTBP▼ -22.6%on this news· ran to -38% by day 3
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
GT Biopharma has received FDA clearance for a new IND for GTB-5550 targeting multiple myeloma. The initiation of a Phase 1 trial is pending grant funding, while ongoing trials for solid tumors continue. The company is optimistic about the potential of its TriKE platform, supported by promising preclinical results.
Read more →GTBP▲ +39.3%on this news· ran to +88% by day 1shared move
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
GT Biopharma will host a live presentation on September 11, 2026, to discuss the development of its TriKE® platform for cancer treatment. The event will feature insights from CEO Michael Breen and Dr. Jeffrey Miller, focusing on clinical progress in treating blood cancers and solid tumors. Attendees can expect discussions on dose levels and future milestones.
Read more →GTBPGT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma reported its second quarter 2026 financial results, highlighting ongoing Phase 1 trials for its TriKE candidates GTB-3650 and GTB-5550. The company anticipates updates in the second half of 2026, supported by a cash balance of approximately $5.1 million. Despite increased R&D and SG&A expenses, the company aims for IND clearance for additional assets this year.
Read more →GTBP▼ -7.6%on this newsshared move
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma has announced advancements in its pipeline due to the implementation of AI-based technologies. These initiatives are expected to enhance the discovery and development of tumor-targeting engagers and multi-domain proteins, potentially leading to new candidates entering pre-IND development by 2027. The company aims to improve clinical success rates while reducing costs and timelines.
Read more →GTBP▼ -10.3%on this newsshared move
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma reported its first quarter 2026 financial results, highlighting ongoing Phase 1 trials for GTB-3650 and GTB-5550. The company has sufficient cash to fund operations through Q4 2026. Despite an increase in net loss, the advancement of three TriKE candidates into clinical trials marks a significant milestone for the company.
Read more →GTBP▲ +40.4%on this newsshared move
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
GT Biopharma has announced the dosing of the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted NK cell engager aimed at treating solid tumors. The trial will initially focus on prostate cancer patients during the dose escalation phase, with updates expected in the second half of 2026. The study will evaluate safety, tolerability, and preliminary anti-tumor activity across various tumor types.
Read more →GTBP▲ +5.7%on this news
GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma, Inc. announced its participation in the 38th Annual Roth Conference scheduled for March 22-24, 2026. Michael Breen, the Executive Chairman and CEO, will present on March 24 at 1:30 PM PDT. The company will also hold one-on-one meetings with investors during the event, showcasing its commitment to investor relations.
Read more →GTBPGT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma reported its financial results for 2025, highlighting ongoing Phase 1 trials for GTB-3650 and GTB-5550. The company anticipates significant milestones in 2026, including the initiation of the GTB-5550 trial. Despite a net loss of $28.4 million, GT Biopharma maintains a strong cash position to support its operations through Q4 2026.
Read more →GTBPGT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma, Inc. will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026. Michael Breen, the Executive Chairman and CEO, will present and engage in panel discussions, along with one-on-one investor meetings. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE platform.
Read more →GTBPGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GT Biopharma has received FDA clearance for its IND application for GTB-5550, a TriKE® targeting B7-H3 in solid tumors. The Phase 1 trial is set to begin in mid-2026, focusing on advanced prostate, ovarian, and pancreatic cancers. The trial will assess safety, tolerability, and preliminary anti-tumor activity across multiple solid tumor types. This development is seen as a pivotal step in advancing immunotherapy for patients with limited treatment options.
Read more →GTBPFunctional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
GT Biopharma, Inc. has submitted an investigational new drug application for GTB-5550, a B7-H3-targeted NK cell engager aimed at treating solid tumors. This submission is part of a broader trend in precision medicine, shifting towards platform-based biologics. The company is also advancing its Phase 1 trial for GTB-3650, targeting blood cancers. Both therapies leverage GT Biopharma's proprietary TriKE platform.
Read more →GTBP▲ +10.6%on this newsshared move
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma has submitted an IND application for GTB-5550, a novel NK cell engager targeting B7-H3 solid tumors. The company plans to initiate a Phase 1 trial in 2026, building on insights from its ongoing GTB-3650 trial in myeloid blood cancer. The trial aims to explore safety and efficacy across multiple solid tumor types.
Read more →GTBP▲ +26.1%on this news
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma, Inc. reported its financial results for Q3 2025 and provided an update on its clinical trials. The ongoing Phase 1 trial for GTB-3650, aimed at treating relapsed or refractory CD33 expressing hematologic malignancies, continues to recruit patients, with results expected in Q1 2026. The company plans to submit an IND application for its conditionally promising GTB-5550 by early 2026. Despite a net loss reported for the quarter, the company remains optimistic about its clinical advances and has enough cash to sustain operations into the next year.
Read more →GTBP▲ +9%on this news
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma has successfully completed the safety review for Cohort 3 of its Phase 1 trial for GTB-3650, allowing progression to Cohort 4. The trial will evaluate the drug's efficacy in patients with relapsed or refractory CD33 expressing hematologic malignancies. The next update is anticipated in Q1 2026, with potential for further dose escalation.
Read more →GTBP▲ +10.6%on this news
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025. Michael Breen, the Executive Chairman and CEO, will represent the company at the event, which will include opportunities for one-on-one meetings. This participation highlights GT Biopharma's focus on immuno-oncology and its proprietary TriKE® platform.
Read more →GTBPGT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company is progressing with its Phase 1 trial for GTBP-3650 and plans to submit an IND for GTB-5550 TriKE® by Q4 2025. Investors can schedule one-on-one meetings during the conference.
Read more →GTBP▼ -7.6%on this news· ran to -26% by day 3
GT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma reported its second quarter 2025 financial results, highlighting strong enrollment in its Phase 1 trial for GTB-3650. The trial is progressing well, with a successful safety review and early signs of immunological activity. Financially, the company has reduced R&D and SG&A expenses, but reported a net loss of $1.4 million.
Read more →GTBPGT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma has advanced to Cohort 3 of its Phase 1 trial for GTB-3650 after a successful safety review of Cohort 2. The trial evaluates GTB-3650 for relapsed or refractory CD33 expressing hematologic malignancies. Initial results from earlier cohorts show promising immune activity, with plans to release more data in 2025.
Read more →About GT Biopharma, Inc.
Headquarters505 MONTGOMERY STREET, SAN FRANCISCO, CA, 94111
BIOPHARMAWATCH ELITE PLUS
Trade the next GTBP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime